Products - Metabolic conditions | Topic | NICE

Showing 5 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Polyendocrine Metabolic Ovarian Syndrome (PMOS)
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
11 August 2026
Expected publication date:
9 December 2026
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Elamipretide for treating Barth syndrome in people of any age [ID6545]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC